The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Multidisciplinary collaborative approach to care is required for patients with hematological malignancies in pregnancy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback